CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Latest Information Update: 23 May 2025
At a glance
- Drugs Abemaciclib (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Ramucirumab (Primary) ; Temozolomide (Primary) ; Vinorelbine (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms CAMPFIRE
- Sponsors Eli Lilly and Company
Most Recent Events
- 27 Sep 2024 Planned End Date changed from 1 May 2026 to 1 May 2027.
- 27 Sep 2024 Planned primary completion date changed from 1 May 2026 to 1 May 2027.
- 24 Aug 2023 New trial record